PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$65.37
−3.87%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$68.00
From 52W high−27.00%
Volume3.66M
Market cap$5.46B
P/E (TTM)—
P/S (TTM)5.4x
Div yield—
Key dataSep 18, 2026
Open
$68.00
From 52W high
−27.00%
Volume
3.66M
Market cap
$5.46B
ValuationView details →
P/E (Fwd)
52.8x
EV/EBITDA
22.6x
P/E (TTM)
—
RSI (14)
37.8
MomentumView details →
1D Return
−3.87%
YTD Return
−12.96%
SummaryUpdated Jun 1, 2026
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biopharmaceutical company founded in 1998 and headquartered in South Plainfield, New Jersey. The company went public in June 2013 and has evolved from a research-focused organization into a commercial-stage biopharmaceutical company with multiple marketed products. PTC specializes in discovering, developing, and commercializing treatments for rare diseases, with a particular focus on genetic disorders that affect small patient populations with high unmet medical needs.
Similar companies
Latest newsMore news →
PTC Therapeutics agreed to acquire from Sangamo Therapeutics all rights to ST-920, an AAV gene therapy product candidate for Fabry disease, for an upfront payment of $111 million plus up to $100 million in contingent milestone payments.23d agoPTC Therapeutics announced a planned acquisition of Sangamo Therapeutics' BLA-stage ST-920 Fabry disease gene therapy program, leveraging existing regulatory and commercial infrastructure.39d agoPTC Therapeutics reported Q2 2026 earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share, compared to a loss of $0.83 per share a year ago.52d ago